Table 2.
Total costs due to TB and household economic status, by drug susceptibility test
| Variables | RS | RMR | MDR | P-value* |
|---|---|---|---|---|
| Total costs due to TB (US$) | ||||
| Mean (SD.) | 2094.5 (2676.7) | 7669.1 (9649.4) | 10,802.1 (10,219.4) | |
| Median(p25,p75) | 1377.8 (740.72503.7) | 3622.2 (1159.312029.6) a | 7355.6 (3129.614255.6) a | < 0.001 |
| Medical costs share of total costs (%) | ||||
| Mean (SD.) | 67.7 (24.4) | 75.6 (24.1) | 64.7 (31.1) | |
| Median(p25,p75) | 70.8 (53.8,87.2) | 79.9 (63.3,94.5) | 75.7 (52.9,87.5) | 0.155 |
| Direct non-medical costs share of total costs (%) | ||||
| Mean (SD.) | 25.4 (22.7) | 20.4 (27.6) | 27.9 (30.7) | |
| Median(p25,p75) | 19.9 (8.5,34.6) | 8.2 (3.1,24.4) | 15.6 (8.6,35.1) | 0.059 |
| Indirect costs share of total costs (%) | ||||
| Mean (SD.) | 7.7 (13.7) | 6.9 (8.7) | 11.0 (18.5) | |
| Median(p25,p75) | 0.0 (0.0,11.4) | 2.9 (0.0,13.9) | 2.9 (0.0,14.7) | 0.118 |
| household’s pre-TB annual income (US$) | ||||
| Mean (SD.) | 14,375.6 (10,762.1) | 14,732.3 (6863.8) | 14,510.6 (14,399.1) | |
| Median(p25,p75) | 11,851.9 (7407.417777.8) | 14,814.8 (8692.620729.6) | 11,918.5 (8114.815633.3) | 0.446 |
| Total costs share of household’s pre-TB annual income (%) | ||||
| Mean (SD.) | 21.6 (24.6) | 29.5 (32.9) | 46.3 (34.1) | |
| Median(p25,p75) | 12.8 (5.7,26.8) | 12.3 (5.2,50.1) | 42.3 (14.0,74.4) a, b | < 0.001 |
Note: US$: United States dollar
A currency exchange rate of Chinese RMB 675 Yuan to US$ 100 Yuan (at the end of 2017)
RS rifampicin-susceptible
RMR rifampicin-monoresistant
MDR multidrug-resistant
*Kruskal Wallis test
Pairwise comparisons were performed by post-hoc analyses with Bonferroni adjustment (3 comparisons: P-value< 0.017)
asignificant compared to RS
bsignificant compared to RMR